The muscle wasting panic around GLP-1 medications has outrun the evidence
For example, if travelling from the UK to Australia (approximately 10 hours ahead), you may need guidance on whether to skip, delay, or adjust your injection schedule
2024, article 102920, Tchang, Beverly, et al
Semaglutide GLP-1 S, on the other hand, is studied within a much broader and more validated use case, with trial data reporting average body weight reductions exceeding 14% over 68 weeks a proof point that has made GLP-1 receptor agonists a far more established research category for metabolic and weight-related studies than growth hormone fragment peptides like AOD-9604
Clinical supply
If you were to inject research-grade tesamorelin into your body, you run the risk of introducing contaminants that could cause serious harm